The termination of the Roosevelt deal removes near-term M&A upside, but the $2.1M cash injection and cost discipline may extend runway. Traders should monitor whether Zola's growth can offset legacy revenue losses and if new strategic alternatives emerge.
Price Chart
Executive Summary
Arcadia Biosciences reported a 4% year-over-year decline in full-year 2025 revenue despite a 17% increase in Zola® coconut water sales, offset by the absence of prior-year GLA oil sales. The company improved its net loss significantly, reducing it by 67% due to lower SG&A expenses and non-operating gains, while securing $2.1 million from preferred investment option exercises after terminating a proposed business combination with Roosevelt Resources.
Key Financial Metrics
Key Facts
- Zola® revenues increased 17% year-over-year in 2025, driven by higher distribution and sales volume.
- Total 2025 revenue declined 4% to $4.858 million due to $756,000 in absent GLA oil sales from 2024.
- Net loss attributable to common stockholders improved 67% to $2.3 million in 2025 from $7.0 million in 2024.
- SG&A expenses decreased by $2.6 million year-over-year, contributing significantly to improved losses.
- Company secured $2.1 million in gross proceeds from exercise of preferred investment options.
- Proposed business combination with Roosevelt Resources was terminated.
Financial Impact
Revenue down 4% YoY ($187K decline), but net loss improved by $4.7M due to cost reductions and gains; $2.1M cash infusion strengthens near-term liquidity.
Risk Factors
- Continued reliance on non-operating gains masks weak core revenue performance.
- Termination of business combination reduces potential for near-term liquidity event or balance sheet relief.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | SC 13G | $0.2800 | awaiting T+60 | — | $0.1518 (−45.79%) |
Sep 15, 2026 5w ago | 8-K | $0.4310 | awaiting T+60 | — | $0.1518 (−64.78%) |
Jul 9, 2026 15w ago | EFFECT | $0.6755 $0.2882 | ▲ +57.34% | ▲ +58.97% | $0.1518 (+77.53%) |
Jul 2, 2026 16w ago | 8-K | $0.7330 $0.3080 | ▼ −57.98% | ▼ −61.55% | $0.1518 (−79.29%) |
Jun 26, 2026 17w ago | S-3 | $0.7190 $0.4480 | ▲ +37.69% | ▲ +42.08% | $0.1518 (+78.89%) |
Jun 15, 2026 19w ago | 8-K | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9180 $0.4530 | ▲ +50.65% | ▲ +51.31% | $0.1518 (+83.46%) |
May 14, 2026 23w ago | 8-K | $0.9560 $0.6699 | ▲ +29.93% | ▲ +34.44% | $0.1518 (+84.12%) |
Apr 30, 2026 25w ago | 10-K/A | $1.12 $0.6300 | ▼ −43.75% | ▼ −46.82% | $0.1518 (−86.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers